STUDYING THE POSSIBLE MUTAGENIC PROPERTIES OF NEW MEDICINE ON THE BASIS OF COMPLEX LITHIUM
CITRATE, ALUMINUM OXIDE AND POLYMETHILSILOXANE
Vladimir Iosifovich KONENKOV1, Maksim Aleksandrovich KOROLEV1, Aleksey Aleksandrovich CHURIN2, Olga Leonidovna VORONOVA2, Oksana Vladimirovna NEUPOKOEVA2, Lubov Nikiforovna RACHKOVSKAYA1, Anna Veniaminovna SHURLYGINA1, Margarita Vladimirovna ROBINSON1, Anastasiya Anatolevna KOTLYAROVA1, Tatyana Viktorovna POPOVA1, Edmund Edmundovich RACHKOVSKIY1, Pavel Gennadievich MADONOV1, Andrey Yurevich LETYAGIN1
1Research Institute of
Clinical and Experimental Lymphology - Branch of Federal Research Center
Institute of Cytology and Genetics of SB RAS
2Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk Scientific Research Center
Keywords: мутагенность, лекарственное средство на основе комплекса лития цитрата, полиметилсилоксана и оксида алюминия, Drosоphila melanogaster, соматические рекомбинации, мыши CBA, доклинические исследования, mutagenicity, drug based on complex lithium citrate, polymethylsiloxane and alumina oxide, Drosophila melanogaster, somatic recombination, CBA mice, preclinical research
Abstract
Aim of the study was to
investigate the possible mutagenic properties of a new drug based on a
lithium-containing substance - a complex of lithium citrate,
polymethylsiloxane and aluminum oxide. Material and methods. Methods for
testing mutagenicity using chromosomal aberrations in the bone marrow
cells of CBA mice and somatic recombination in Drosophila melanogaster
were used. Results. It was shown that a single intragastric
administration of drug at a dose of 5000 mg/kg and a fivefold course of
administration at a dose of 400 mg/kg to CBA mice did not increase the
level of cytogenetic disorders in bone marrow cells. The study of the
lithium complex drug in a somatic mosaicism test revealed that the
preparation at a dose of 2000 mg/kg does not increase the frequency of
mutations in Drosophila melanogaster . Conclusion. A single intragastric
administration of the studied drug at a dose of 5000 mg/kg and its
course administration (400 mg/kg × 5) do not increase the level of
cytogenetic disorders in the bone marrow cells of CBA mice. In the
somatic recombination (mosaicism) test system on D. melanogaster , no
increase in the appearance of mutant setae and spots on the body and
head was observed when using yellow and singed markers. The results of
the study indicate that the studied drug does not have mutagenic
properties.
|
